ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)

13.820 -0.040 (-0.29%) At close: 04:08PM HKT

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Unit 15
1000 Zhangheng Road China (Shanghai) Pilot Free Trade Zone Pudong New Area
Shanghai
China
86 21 3801 6387
https://www.immuneonco.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Tian Wenzhi	Founder, CEO, Chief Scientific Officer & Chairman of the Board	3.93M	N/A	1964
Mr. Li Song	VP of R&D and Executive Director	1.06M	N/A	1985
Dr. Lu Qiying	Senior VP & Chief Medical Officer	N/A	N/A	1974
Dr. Xiong Zikai Ph.D.	Senior Vice President	N/A	N/A	1980
Dr. Xiaodong Gan	Senior Vice President	N/A	N/A	1963
Mr. Zhang Ruliang	Deputy GM & Senior VP	N/A	N/A	1984
Ms. Guan Mei	Secretary, Director of the Financing and Investment Strategy Department & Executive Director	N/A	N/A	1983
Mr. Kin Wai Li	Joint Company Secretary	N/A	N/A	1989

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People's Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. The company was incorporated in 2015 and is headquartered in Shanghai, China.

Corporate governance

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.